Roflumilast in Asian patients with COPD: A randomized placebo-controlled trial

被引:27
作者
Lee, Sang-Do [1 ]
Hui, David S. C. [2 ]
Mahayiddin, Aziah A. [3 ]
Roa, Camilo C., Jr. [5 ]
Kwa, Kheng Hoe [4 ]
Goehring, Udo-Michael [6 ]
Bredenbroeker, Dirk [6 ]
Kuo, Han-Pin [7 ]
机构
[1] Univ Ulsan, Dept Pulm & Crit Care Med, Clin Res Ctr Chron Obstruct Airway Dis, Asan Med Ctr,Coll Med, Seoul 138736, South Korea
[2] Chinese Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China
[3] Kuala Lumpur Gen Hosp, Kuala Lumpur, Malaysia
[4] Nycomed Malaysia Sdn Bhd, Kuala Lumpur, Malaysia
[5] Philippine Gen Hosp, Manila, Philippines
[6] Nycomed GmbH, Constance, Germany
[7] Chang Gung Mem Hosp, Taipei 10591, Taiwan
关键词
Asia; chronic obstructive pulmonary disease; phosphodiesterase; 4; inhibitor; roflumilast; OBSTRUCTIVE PULMONARY-DISEASE; PDE4 INHIBITOR ROFLUMILAST; CLINICAL-TRIALS; PREVALENCE; SPIROMETRY; REDUCTION;
D O I
10.1111/j.1440-1843.2011.02038.x
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background and objective: Roflumilast, an oral, selective phosphodiesterase 4 inhibitor, has been shown to reduce exacerbations and improve pulmonary function in patients with COPD. This study examined the efficacy, safety and tolerability of roflumilast in Asian patients with COPD. Methods: Patients with COPD were randomized 1:1 to enter a 12-week treatment period and receive either oral roflumilast, 500 mu g once daily, or placebo, following a single-blind, 4-week baseline period in which all patients received placebo. The primary end point was mean change in FEV(1) from baseline to each postran-domization visit during the treatment period. Other spirometric lung function measurements were evaluated as secondary end points. COPD exacerbations were monitored. Safety was assessed from clinical laboratory tests, vital signs, physical examination (including electrocardiogram) and monitoring of adverse events (AEs). Results: Of 551 patients recruited, 410 were randomized and received at least one dose of study medication (roflumilast, n = 203; placebo, n = 207). Superiority of roflumilast over placebo was demonstrated by a statistically significant difference in postbron-chodilator FEV(1) (79 mL, P < 0.0001). Other spirometry end points, including prebronchodilator FEV(1), pre- and postbron-chodilator FEV(6), forced vital capacity and peak expiratory flow significantly favoured roflumilast over placebo. AEs were more common with roflumilast than with placebo, but were comparable with those reported in previous studies. Conclusions: Roflumilast, 500 mu g once daily, improves pulmonary function in Asian patients with COPD. The safety and tolerability of roflumilast in this population was similar to that in a Caucasian population.
引用
收藏
页码:1249 / 1257
页数:9
相关论文
共 23 条
[11]  
Global initiative for chronic Obstructive Lung Disease, 2010, GLOB STRAT DIAGN MAN
[12]   Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD [J].
Grootendorst, Diana C. ;
Gauw, Stefanie A. ;
Verhoosel, Renate M. ;
Sterk, Peter J. ;
Hospers, Jeannette J. ;
Bredenbroeker, Dirk ;
Bethke, Thomas D. ;
Hiemstra, Pieter S. ;
Rabe, Klaus F. .
THORAX, 2007, 62 (12) :1081-1087
[13]   Prevalence of chronic obstructive pulmonary disease in Korea - A population-based spirometry survey [J].
Kim, DS ;
Kim, YS ;
Jung, KS ;
Chang, JH ;
Lim, CM ;
Lee, JH ;
Uh, ST ;
Shim, JJ ;
Lew, WJ .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2005, 172 (07) :842-847
[14]  
Maranetra Khun Nanta, 2002, Journal of the Medical Association of Thailand, V85, P1147
[15]  
McIvor RA, 2010, EXPERT REV RESP MED, V2, P539
[16]   Standardisation of spirometry [J].
Miller, MR ;
Hankinson, J ;
Brusasco, V ;
Burgos, F ;
Casaburi, R ;
Coates, A ;
Crapo, R ;
Enright, P ;
van der Grinten, CPM ;
Gustafsson, P ;
Jensen, R ;
Johnson, DC ;
MacIntyre, N ;
McKay, R ;
Navajas, D ;
Pedersen, OF ;
Pellegrino, R ;
Viegi, G ;
Wanger, J .
EUROPEAN RESPIRATORY JOURNAL, 2005, 26 (02) :319-338
[17]   PDE4 inhibitors: a review of current developments (2005-2009) [J].
Pages, Lluis ;
Gavalda, Amadeu ;
Lehner, Martin D. .
EXPERT OPINION ON THERAPEUTIC PATENTS, 2009, 19 (11) :1501-1519
[18]   Roflumilast -: an oral anti-inflammatory treatment for chronic obstructive pulmonary disease:: a randomised controlled trial [J].
Rabe, KF ;
Bateman, ED ;
O'Donnell, D ;
Witte, S ;
Bredenbröker, D ;
Bethke, TD .
LANCET, 2005, 366 (9485) :563-571
[19]   Reduction of exacerbations by the PDE4 inhibitor roflumilast - the importance of defining different subsets of patients with COPD [J].
Rennard, Stephen I. ;
Calverley, Peter M. A. ;
Goehring, Udo M. ;
Bredenbroeker, Dirk ;
Martinez, Fernando J. .
RESPIRATORY RESEARCH, 2011, 12
[20]   COPD in asia - Where East meets West [J].
Tan, Wan C. ;
Ng, Tze P. .
CHEST, 2008, 133 (02) :517-527